Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 4,640 | 0 | 0 | 0 | 0 |
| Gross Profit | 4,640 | N/A | N/A | N/A | N/A |
| Operating Expenses | 51,560 | 46,092 | 42,404 | 44,901 | 56,819 |
| Operating Income | -46,920 | -46,092 | -42,404 | -44,901 | -56,819 |
| Interest Expense | 343 | 300 | 313 | 344 | 268 |
| Other Income | 4,586 | 3,785 | 3,907 | 3,845 | 6,144 |
| Pre-tax Income | -42,677 | -42,607 | -38,810 | -41,400 | -50,943 |
| Net Income Continuous | -42,677 | -42,607 | -38,810 | -41,400 | -50,943 |
| Net Income | $-42,677 | $-42,607 | $-38,810 | $-41,400 | $-50,943 |
| EPS Basic Total Ops | -0.13 | -0.18 | -0.17 | -0.19 | -0.23 |
| EPS Basic Continuous Ops | -0.13 | -0.18 | -0.17 | -0.19 | -0.23 |
| EPS Diluted Total Ops | -0.13 | -0.18 | -0.17 | -0.19 | -0.23 |
| EPS Diluted Continuous Ops | -0.13 | -0.18 | -0.17 | -0.19 | -0.23 |
| EPS Diluted Before Non-Recurring Items | -0.13 | -0.18 | -0.17 | -0.19 | -0.23 |
| EBITDA(a) | $-45,588 | $-44,108 | $-40,168 | $-42,727 | $-54,884 |